AG真人官方

Biogen Inc. (BIIB) filed a Form 144 indicating that an affiliate intends to sell up to 2,223 common shares through Fidelity Brokerage Services on or about 07/08/2025. The proposed sale has an aggregate market value of $300,105, implying a price of roughly $135 per share. With 146,527,832 shares outstanding, the transaction represents only about 0.0015 % of Biogen鈥檚 equity float and is therefore immaterial to overall share supply.

The shares were acquired via two restricted-stock vesting events on 02/08/2025 (1,153 shares) and 02/10/2025 (1,070 shares) as compensation. The filer reports no sales in the past three months and did not disclose adoption of a Rule 10b5-1 trading plan. Form 144 is a notice of proposed disposition; the sale may or may not be executed.

No additional operational, earnings, or strategic information about Biogen is provided in this filing. Investors typically view such small-scale insider sales as routine liquidity events rather than signals of fundamental change.

Robinhood Markets, Inc. (HOOD) has filed a Form 144 indicating the intended sale of 250,000 common shares with an estimated aggregate market value of $23.6 million. The shares are slated to be sold through Morgan Stanley Smith Barney LLC on or about 07 July 2025 on the NASDAQ.

The filing lists 767,047,021 shares outstanding; the contemplated transaction therefore represents roughly 0.03 % of the float, suggesting limited dilution or trading-volume impact. The notice also discloses that 750,000 shares were sold on 01 July 2025 for $69.95 million under a Rule 10b5-1 plan attributed to Vladimir Tenev.

• The current sale plus the earlier disposal totals 1.0 million shares, generating about $93.5 million for the insider within a single week.
• The seller affirms awareness of no undisclosed adverse information, and reliance on a written 10b5-1 plan mitigates insider-trading risk.

While purely administrative and not a guarantee of execution, the filing signals continued insider selling activity. Investors often watch such patterns for sentiment clues, even when the share count is immaterial relative to the company鈥檚 overall capitalization.

Biogen held its 2025 Annual Meeting of Stockholders on June 17, 2025, with three key matters put to vote. All eleven nominated directors were successfully elected to serve one-year terms until the 2026 annual meeting, with notable strong support for Lloyd Minor, Menelas Pangalos, and Monish Patolawala, each receiving over 114 million votes in favor.

Key voting outcomes include:

• Independent Auditor Appointment: PricewaterhouseCoopers LLP was ratified as the independent auditor for FY2025 with strong support (120,065,433 votes in favor)
• Say-on-Pay Vote: The executive compensation package was approved, though with more divided support - 78.5 million votes in favor versus 37.1 million against

The relatively split vote on executive compensation (67.8% approval) suggests some shareholder concerns about leadership remuneration. The high broker non-votes (10.2 million) across most items indicate significant holdings by institutional investors who did not provide voting instructions.

Form 4 overview: On 06/17/2025 Biogen (BIIB) director Menelas N. Pangalos received 2,370 restricted stock units (RSUs) at no cost. The units convert to common stock on the earlier of the company鈥檚 next annual meeting or 06/17/2026. After the award, the director beneficially owns 2,370 BIIB shares directly.

No shares were sold or disposed of; the filing reflects standard director compensation. Given Biogen鈥檚 large share count, the issuance is immaterial to dilution or valuation and therefore neutral for investors.

Biogen Inc. (BIIB) 鈥� Form 4 insider transaction

Independent director Dr. Lloyd Minor reported the acquisition of 2,370 shares of Biogen common stock on 17-Jun-2025. The transaction code 鈥淎鈥� indicates that the shares were awarded rather than purchased on the open market; the reported price is $0, consistent with a restricted stock or director equity grant. Following the grant, Dr. Minor鈥檚 total direct ownership stands at 2,370 shares. No derivative securities were involved, and there were no dispositions.

The filing is routine director compensation disclosure and does not reveal any change in strategy, operations, or financial condition. However, fresh equity ownership marginally strengthens alignment between the director and shareholder interests.

Form 4 overview: On 06/17/2025, Biogen Inc. (BIIB) director Monish D. Patolawala reported the acquisition of 2,370 shares of common stock at a stated price of $0.00, suggesting a share grant or similar equity award. Following the transaction, Mr. Patolawala now beneficially owns 3,710 shares, held directly.

The filing contains no derivative security activity, sales, or monetary purchase and therefore does not indicate cash outlay or immediate market transactions. While the increase in personal holdings modestly aligns the director鈥檚 interests with shareholders, the size of the transaction is relatively small against Biogen鈥檚 roughly $33 billion market capitalization, implying limited near-term market impact.

Biogen Inc. (BIIB) 鈥� Form 4 insider filing

Director Jesus B. Mantas reported one transaction dated 06/17/2025. The filing shows an "A" transaction code (acquisition) for 2,370 shares of Biogen common stock at a stated price of $0.00, indicating a stock award or grant. After this transaction, the director鈥檚 direct beneficial ownership increases to 9,758 shares. No derivative security transactions were reported, and there are no sales or dispositions disclosed in the filing.

The form was signed by an attorney-in-fact on 06/18/2025. No other insiders or joint filers are involved, and there is no indication that the reporting person is no longer subject to Section 16.

Biogen Inc. (BIIB) has filed a Form 4 indicating that director William A. Hawkins acquired 2,370 shares of the company鈥檚 common stock on 06/17/2025. The transaction is coded 鈥淎鈥� (acquisition) and carries a reported price of $0, suggesting the shares were granted rather than purchased on the open market. Following the transaction, Hawkins鈥� direct beneficial ownership stands at 8,860 shares.

The filing confirms Hawkins鈥� role as a director and notes the document was signed on 06/18/2025 by attorney-in-fact Wendell Taylor. No derivative security activity or additional transactions were reported.

Biogen Director Maria C. Freire reported the acquisition of 2,370 shares of Common Stock on June 17, 2025. The shares were acquired at $0 per share, suggesting this was likely a stock grant as part of director compensation.

Following this transaction, Freire now beneficially owns a total of 6,815 shares directly. The filing indicates this was a direct ownership transaction, with no indirect holdings reported. The Form 4 was signed by Wendell Taylor as attorney-in-fact for Dr. Freire on June 18, 2025.

This insider transaction represents a notable increase in Freire's equity stake in Biogen, demonstrating continued alignment between director and shareholder interests. No derivative securities were involved in this transaction.